To help high-risk COVID-19 patients, AstraZeneca is testing diabetes treatment
AstraZeneca (NASDAQ: AZN) and the Mid America Heart Institute in Saint Luke in Kansas City have started a clinical trial in which they administer Farxiga to hospitalized COVID-19 patients, which is actually a treatment for diabetes. Although the blood sugar lowering drug does nothing to combat the coronavirus itself, investigators are looking for signs that it may reduce the risk of some of its life-threatening complications.
Farxiga helps patients with type 2 diabetes control their blood sugar by helping the passage of glucose from the bloodstream to the bladder. It is approved to reduce the risk of heart failure in high risk diabetic patients.
The DARE-19 trial will recruit hospitalized COVID-19 patients who also have cardiovascular, metabolic or kidney problems. The risks of serious complications such as organ failure make this group extremely vulnerable to the coronavirus. And since Farxiga is already known to reduce the risk of long-term fatal complications for these patients, there is a good chance that it may provide them with some benefit as they battle the additional health threats that come with a case. severe COVID. -19.
Everything except the kitchen faucet
Tackling viruses is not one of AstraZeneca’s main areas of focus, but the company is trying to help the global response to COVID-19 in any way it can. Earlier this month, he began a randomized trial in which critically ill coronavirus patients were treated with Calquence, a tyrosine kinase (BTK) inhibitor from Bruton normally used to treat cancer patients. some blood.
Some patients with COVID-19 experience such a frenzied immune system response that their bodies’ efforts to fight off the virus become more dangerous to them than the virus itself. Calquence helps patients with leukemia and lymphoma by limiting the uncontrolled activity of immune cells, which could also be helpful for patients with severe reactions to the coronavirus.
This article represents the opinion of the author, who may disagree with the “official” recommendation position of a premium Motley Fool consulting service. We are motley! Challenging an investment thesis – even one of our own – helps us all to think critically about investing and make decisions that help us become smarter, happier, and richer.